ArticleThe European respiratory journal2024
Exacerbation history and blood eosinophil count prior to diagnosis of COPD and risk of subsequent exacerbations.
Article in The European respiratory journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Astegolimab for chronic obstructive pulmonary disease with frequent exacerbations: pooled analysis of the ALIENTO and ARNASA trials.American journal of respiratory and critical care medicine · 2026Trial
- COPD Patients with a High Exacerbation Risk: Baseline Data Analysis of a National Chinese Prospective Multi-Center Study of Quality Improvement Project.International journal of chronic obstructive pulmonary disease · 2026Trial
- Prevalence of type 2 multimorbidities in COPD compared to asthma and relationship to blood eosinophilic counts.ERJ open research · 2026Article
- Real-World Outcomes across Baseline Risk Profiles in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate in Spain: Insights from the ORESTES Study.Pulmonary therapy · 2026Article
- CT image-based machine learning models for predicting blood eosinophil levels in acute exacerbation of chronic obstructive pulmonary disease.BMC pulmonary medicine · 2026Article
- Low sRAGE Level is Associated with Increased Future Exacerbation Risk in Mild-to-Moderate COPD and Patients with Chronic Bronchitis Symptoms.International journal of chronic obstructive pulmonary disease · 2026Observational
- The Role of Advanced Lung Cancer Inflammation Index in Predicting COPD Exacerbation Risks.International journal of chronic obstructive pulmonary disease · 2026Article
- Assessment of the clinical prognosis of patients with chronic obstructive pulmonary disease using combined blood and sputum eosinophil counts.BMJ open respiratory research · 2025Article
- Treatment needs in mild-to-moderate chronic obstructive pulmonary disease: evidence from longitudinal studies.Journal of thoracic disease · 2025Article
- Pragmatic Evaluation of an Improvement Program for People Living With Modifiable High-Risk COPD Versus Usual Care: Protocols for the Cluster Randomized PREVAIL Trial.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2025Article
- Εosinophilic Chronic Obstructive Pulmonary Disease. What Do We Know So Far?Pulmonary therapy · 2025Review
- Association between Prognostic Nutritional Index and Mortality Risk in Critically Ill Patients with Chronic Obstructive Pulmonary Disease: A Retrospective Study.International journal of chronic obstructive pulmonary disease · 2025Article
- Long-term exposure to ambient air pollutant and acute exacerbations of chronic obstructive pulmonary disease: a retrospective cohort study in Xinjiang, China.Frontiers in public health · 2025Article
- Oral Corticosteroid-Related Healthcare Resource Utilization and Associated Costs in Patients with COPD.Advances in therapy · 2025Observational
- Reply to: Is there a kindling effect in COPD exacerbations?The European respiratory journal · 2024Article
- Advancing towards personalized medicine: Practical specifications for management of treatable traits in patients with COPD exacerbations.Therapeutic advances in respiratory diseaseReview
- Prevalence and Clinical Outcomes of Eosinophilic COPD in a Saudi Population: A Retrospective Study.Saudi journal of medicine & medical sciencesArticle
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrior exacerbation history is used to guide initial maintenance therapy in COPD; however, the recommendations were derived from patients already diagnosed and treated.
methodsWe assessed the rates of moderate (
results73 189 patients were included. 61.9% had no exacerbations prior to diagnosis, 21.5% had 1 moderate, 16.5% had ≥2 moderate and 0.3% had ≥1 severe. 50% were started on maintenance therapy. In patients not started on maintenance therapy the rates of moderate exacerbations in the year after diagnosis in patients with no, 1 moderate, ≥2 moderate and ≥1 severe prior exacerbations were 0.34 (95% CI 0.33-0.35), 0.59 (95% CI 0.56-0.61), 1.18 (95% CI 1.14-1.23) and 1.21 (95% CI 0.73-1.69), respectively. Similar results were seen in patients started on maintenance therapy. BEC did not add significantly to the prediction of future exacerbation risk.
conclusionsA single moderate exacerbation in the year prior to diagnosis increases the risk of subsequent exacerbations, and more frequent or severe exacerbations prior to diagnosis are associated with a higher risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.